| Literature DB >> 31016730 |
David Boutboul1,2,3,4, Jehane Fadlallah1,4, Sylvain Chawki1, Claire Fieschi1,4,5, Marion Malphettes1,6, Antoine Dossier7, Laurence Gérard1,2,6, Pierre Mordant4,8,9, Véronique Meignin2,10, Eric Oksenhendler1,2,4,6, Lionel Galicier1,2,6.
Abstract
We retrospectively analysed 71 cases of Unicentric Castleman disease, a rare, usually asymptomatic, benign lymphoproliferative disorder presenting as a unique nodal mass. Although surgery is considered as the gold standard therapy, only 38 patients (54%) underwent initial surgical resection and 95% were cured. An additional 9 patients had surgery after an attempt at medical reduction. Reduction therapy was used in 21 patients with a 55% response rate, but without evidence for an optimal regimen. Radiotherapy was limited to 8 patients because of associated toxicity. Watch and wait was considered in 13 asymptomatic patients and 11 of these remained stable for up to 17 years.Entities:
Keywords: Castleman disease; radiotherapy; surgery; watch-and-wait
Mesh：
Year: 2019 PMID： 31016730 DOI： 10.1111/bjh.15921
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998